Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets 02:14:35 06/10/21 am AEDT			5-day change	1st Jan Change
4.510 ^USD	-5.65%		-2.45%	-

19/08	Cosmos Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/07	Cosmos Health Advances its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C And B2B Channels	CI

Market Cap	10.99M 9.43M 8.81M 8.08M 15.19M 1.05B 15.44M 104M 40.69M 527M 41.28M 40.38M 1.74B	P/E 2026 *	-0.92x	P/E 2027 *	2.76x
Enterprise Value	10.99M 9.43M 8.81M 8.08M 15.19M 1.05B 15.44M 104M 40.69M 527M 41.28M 40.38M 1.74B	EV / Sales 2026 *	0.14x	EV / Sales 2027 *	0.1x
Free-Float	78.25%	Yield 2026 *	-	Yield 2027 *	-

19/08	Cosmos Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/07	Cosmos Health Advances its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C And B2B Channels	CI
14/07	Cosmos Health Inc. And Libytec Pharmaceutical S.A. Enters Distribution And Promotion Agreement For DIABIT-IS X In Greece	CI
14/07	Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug	MT
11/07	Cosmos Health Inc. Launches Subscription-Based Purchasing Model for Its Proprietary Consumer Health Brands	CI
11/07	Cosmos Health Launches Subscription-Based Purchasing Model	MT
08/07	Cosmos Health Inc. Provides Preliminary Revenue Guidance for the Second Quarter and First Half 2026	CI
03/07	Cosmos Health Expands Share Buyback to 3.4 Million Shares	MT
01/07	Cosmos Health Inc. announces an Equity Buyback for $5 million worth of its shares.	CI
30/06	Cosmos Health Inc. authorizes a Buyback Plan.	CI
27/06	Cosmos Health Signs Qatar Distribution Deal With IMC	MT
27/06	Cosmos Health Inc. Signs Distribution Agreement with International Medical Company, and Secures Initial Purchase Order of 31,000 Sky Premium Life Units	CI
24/06	Cosmos Health to Deploy AI-Powered Call Center at Pharma Distribution Unit	MT

19/08	Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway	GL
19/08	Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway	AQ
28/07	Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels	GL
21/07	Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units	GL
18/07	Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases	GL

Cosmos Holdings Inc. Stock OTC Markets

Stocks

COSM

US2214131078

Pharmaceuticals

Valuation: Cosmos Holdings Inc.

Latest news : Cosmos Holdings Inc.

Press Releases: Cosmos Holdings Inc.

News in other languages: Cosmos Holdings Inc.

Quotes and Performance

Managers and Directors: Cosmos Holdings Inc.

Pharmaceuticals Wholesale

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

30/11/24	Dalla farmaceutica al fitness: la corsa all'oro del bitcoin - Crypt On It
28/11/24	De la farmacia al gimnasio: la fiebre del bitcoin - Crypto Recap
05/12/22	Pelè non è in cure palliative - figlia
01/12/22	BASF : lance un agent nacrant naturel à base de cire

Manager	Title	Age	Since
Grigorios Siokas CEO	Chief Executive Officer	60	26/02/2016
Georgios Terzis DFI	Director of Finance/CFO	43	11/11/2020
Nikolaos Bardakis COO	Chief Operating Officer	56	01/02/2023

Director	Title	Age	Since
Demetrios Demetriades BRD	Director/Board Member	58	13/01/2014
Grigorios Siokas CHM	Chairman	60	26/02/2016
John Hoidas BRD	Director/Board Member	59	18/11/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COSMOS HOLDINGS INC.	-5.65%	-2.45%	-	-	10.99M
MCKESSON CORPORATION	-1.79%	-2.85%	+26.12%	+103.06%	99.53B
CARDINAL HEALTH, INC.	-0.06%	+0.29%	+57.60%	+173.56%	54.62B
SIGMA HEALTHCARE LIMITED	0.00%	-2.68%	+2.47%	+279.08%	23.75B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	-0.37%	-1.15%	-13.43%	-14.96%	8.13B
HUADONG MEDICINE CO., LTD	-1.52%	-3.39%	-37.95%	-24.26%	7.42B
SINOPHARM GROUP CO. LTD.	-0.96%	-0.96%	-15.88%	-23.59%	6.66B
H. LUNDBECK A/S	-3.65%	-2.19%	+5.60%	+20.05%	6.55B
GALENICA AG	+0.53%	+0.19%	-4.87%	+16.21%	5.03B
MEDIPAL HOLDINGS CORPORATION	+0.56%	+2.49%	+7.52%	+17.77%	3.71B
Average	-1.30%	-0.62%	+3.02%	+60.77%	23.93B
Weighted average by Cap.	-1.03%	-1.57%	+24.83%	+121.56%

	2026 *	2027 *
Net sales	80.8M 69.31M 64.72M 59.38M 112M 7.72B 113M 764M 299M 3.87B 303M 297M 12.81B	111M 95.04M 88.75M 81.43M 153M 10.59B 156M 1.05B 410M 5.31B 416M 407M 17.56B
Net income	-	-
Net Debt	-	-